Press Releases
Samsung Biologics issues first annual TCFD report
Samsung Biologics published its first report aligned to the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD). The report serves the company’s commitment to providing meaningful transparency on its approach to managing climate-related risks and opportunities across the business.
Last year, Samsung Biologics formally announced its commitment to achieving net zero GHG emissions in its own operations and in its entire supply chain by 2050 or earlier. The company also joined the RE100 initiative to transition its site to 100% renewable electricity. In addition to an environmental management strategy which includes process energy optimization, transitioning to renewable energy, and minimizing the use of disposables, Samsung Biologics has also proactively engaged with suppliers to reduce their direct emissions.
The TCFD report represents an important step to deliver progress; climate change-impact assessments will be integrated into Samsung Biologics’ strategic planning and risk management frameworks to help strengthen its business resilience and adaptation to climate change.
The full text of the 2022 Samsung Biologics TCFD Report can be viewed here.
Samsung Biologics published its first report aligned to the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD). The report serves the company’s commitment to providing meaningful transparency on its approach to managing climate-related risks and opportunities across the business.
Last year, Samsung Biologics formally announced its commitment to achieving net zero GHG emissions in its own operations and in its entire supply chain by 2050 or earlier. The company also joined the RE100 initiative to transition its site to 100% renewable electricity. In addition to an environmental management strategy which includes process energy optimization, transitioning to renewable energy, and minimizing the use of disposables, Samsung Biologics has also proactively engaged with suppliers to reduce their direct emissions.
The TCFD report represents an important step to deliver progress; climate change-impact assessments will be integrated into Samsung Biologics’ strategic planning and risk management frameworks to help strengthen its business resilience and adaptation to climate change.
The full text of the 2022 Samsung Biologics TCFD Report can be viewed here.